Table 2 reports CO by device and treatment intervention characteristics.
Finally, these tools might be of use for ongoing surveillance of medical devices, medications and interventions for clinical outcomes (rather than surrogate endpoints) especially in the ICU where these are sometimes adopted without clear evidence of long-term benefit.
Data are presented as mean (standard deviation) and p-values were adjusted for wear time, type of device, and intervention group.
The groups were similar considering patient characteristics and device and intervention-related aspects, except for chronic kidney disease, atrial fibrillation, QRS width, and defibrillators number, which were higher in the reused group – study group.
Data are presented as means (standard deviation) and p-values are adjusted for wear time, type of device, and intervention group aSignificant cross-sectional differences between weekday and weekend at baseline (N = 570; P < 0.05).
Moreover, with increased understanding will come the promise of improved designs for medical devices and clinical interventions.
The results of this study support a new paradigm and approach in the design and testing of implantable devices and biomedical interventions for diabetic patients.
Despite variations in surgical techniques, intraocular lens material or design, implantation of additional devices, and pharmacological interventions, PCO remains the most frequent long term complication after cataract surgery [ 1].
The enduring vision is to explicate the underlying neurobiology, identify new treatment targets, develop drugs, biologics, devices and refined psychosocial interventions for new targets, and do so in a lifespan context that emphasizes early developmental events and is personalized.
Recent improvements in early detection of hearing loss in newborns, improved hearing aids, surgical implant devices and especially early intervention with parents have led to new opportunities to learn to hear.
